Gufic Biosciences (509079) investor relations material

Executive summary

• FY 2026 was a transition year with full fixed costs from a new facility, a working capital reset, and significant investments in leadership for future growth.

• Q4 FY 2026 marked the strongest quarter ever, with record revenue and EBITDA, and PAT more than doubling year-over-year.

• Achieved commercial production at the advanced Indore facility, targeting global regulated markets and complex injectables.

• Strategic shift in international business to an IP-owned, complex-injectables-led export and licensing model, expanding regulatory approvals and market access.

• Board recommended a final dividend of Re. 0.10 per equity share for FY 2025-26, subject to shareholder approval.

Financial highlights

• Q4 FY 2026 revenue was Rs 252.1 crore, up from Rs 205 crore in Q4 FY 2025; FY 2026 revenue reached Rs 940.5 crore, up from Rs 819.8 crore in FY 2025.

• Q4 FY 2026 EBITDA rose to Rs 44.77 crore (margin 17.73%) from Rs 27 crore (margin 13.17%) year-over-year.

• Q4 FY 2026 PAT increased to Rs 20.5 crore (margin 8.13%) from Rs 8 crore (margin 3.90%) year-over-year.

• FY 2026 EBITDA was Rs 152.9 crore (margin 16.26%), PAT was Rs 63.2 crore (margin 6.72%), both slightly down from FY 2025 due to transition costs.

• Cash and cash equivalents at year-end increased to Rs 6,218.59 lakhs from Rs 1,572.33 lakhs year-over-year.

Outlook and guidance

• Expecting 15% year-over-year revenue growth and 0.5%-1% annual gross margin improvement.

• EBITDA margin projected to rise to 18% in FY 2027, with a long-term target above 20% by 2030.

• No major greenfield CapEx planned for the next two years; only maintenance and strategic investments.

• Indore facility expected to reach 30% utilization and EBITDA breakeven in FY26, with margin accretion from FY27.

• Dividend payout reflects confidence in ongoing profitability and cash flow generation.